AbbVie’s Humira is getting swapped out for Organon’s biosimilar Hadlima on the US Department of Veterans Affairs’ national formulary.
The move marks a big win for Organon as the drug from Merck’s women’s health spinoff competes with eight other biosimilars for a share of Humira’s inflammatory disease market. Hadlima could be the only biosimilar on the VA’s formulary for the next five years, according to the terms of the contract.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.